Weiguang Biology: Jointly invest with relevant partners to establish a project company and build a market-oriented public service platform for cell and gene therapy in Shenzhen.

Weiguang Biology Announcement: The company plans to jointly invest in the establishment of Shenzhen Xihe Life Science and Technology Co., Ltd. with Shenzhen Shenzhen Industry Biopharmaceutical Industry Development Co., Ltd., Shenzhen Cell Valley Biopharmaceutical Co., Ltd. and Shenzhen Saiqiao Bio-innovation Technology Co., Ltd., aiming to build a market-oriented public service platform for cell and gene therapy in Shenzhen. Xihe Life Science and Technology has an initial registered capital of 100 million RMB, with the company subscribing for 40 million RMB, representing a 40% equity stake in Xihe Life Science and Technology.